HONG KONG – China's Luye Pharma Group Ltd. has emerged as a global biotech player by leveraging partnerships around the world, and its 24-year journey is a case study of how a Chinese company can expand, both acquire and protect intellectual property (IP) and deal with cultural challenges that come with global operations. Read More
TOKYO – Japanese pharmaceutical companies are downsizing, bucking a longstanding practice in the country of providing lifetime employment, even as they try to prepare for the possibility of a shrinking industry. Read More
HONG KONG – Lupin Ltd. and Mylan NV will be working together on commercializing a biosimilar Enbrel (etanercept) drug, or YLB-113, in a deal that brings Lupin an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product. Read More
The discovery of how human cells are triggered to undergo cell death could have major implications for development of new drugs for treating cancer, stroke and tissue injury, and immune disorders, according to a study by Australian researchers. Read More
Luoxin Biotechnology Co. Ltd., of Shanghai, and Innovent Biologics Inc., of Hong Kong, said they selected Oracle Argus to help them comply with new drug safety regulations and reporting in China. Mundipharma International Co. Ltd., of Cambridge, U.K., said it extended its partnership with Kolon Life Science, a subsidiary of South Korean conglomerate Kolon Group, to market Invossa-K in Saudi Arabia and the United Arab Emirates. Financial terms were not disclosed. Read More
Immuron Ltd., of Melbourne, Australia, appointed Richard Jay Berman to its board. Berman is a director of three public healthcare companies: Advaxis, Inc., Catasys, Inc. and Cryoport Inc. Read More
This time last year, Athenex Inc. was fresh off its IPO, which grossed $66 million, and embarking on an ambitious strategy to conduct phase III trials of Oraxol, the lead chemotherapeutic from its Orascovery platform, in metastatic breast cancer (MBC) and the phase III program for KX-01, the lead candidate from its Src kinase inhibition platform, to treat actinic keratosis (AK). The Buffalo, N.Y.-based company delivered everything promised in the IPO on time or ahead of schedule, according to CEO Johnson Lau. Read More
